Tabuk Pharmaceuticals Signs a Commercial Agreement with Renapharma AB
Tabuk Pharmaceuticals Manufacturing Company (‘Tabuk’), one of the leading pharmaceutical companies in the Middle East and North Africa region, has entered…
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology
– In subgroup analyses, an overall response rate of 45.5 percent with DS-3201 was observed in patients with B-cell lymphomas…